{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T20:02:36Z","timestamp":1789156956396,"version":"build-2803163510"},"reference-count":41,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1016\/j.ijrobp.2014.12.061","type":"journal-article","created":{"date-parts":[[2015,3,20]],"date-time":"2015-03-20T08:12:06Z","timestamp":1426839126000},"page":"898-906","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":54,"title":["Radium-223 in the Treatment of Osteoblastic Metastases: A Critical Clinical Review"],"prefix":"10.1016","volume":"91","clinical-trial-number":[{"clinical-trial-number":"nct01833520","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"John L.","family":"Humm","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Sartor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Parker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oyvind S.","family":"Bruland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Macklis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2014.12.061_bib1","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1126\/science.1069943","article-title":"Portrait of science. Scientist, technologist, proto-feminist, superstar","volume":"295","author":"Macklis","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.ijrobp.2014.12.061_bib2","series-title":"Marie Curie: A Life","author":"Quinn","year":"1995"},{"key":"10.1016\/j.ijrobp.2014.12.061_bib3","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1667\/RR13483.1","article-title":"Redefining relative biological effectiveness in the context of the EQDX formalism: Implications for alpha-particle emitter therapy","volume":"181","author":"Hobbs","year":"2014","journal-title":"Radiat Res"},{"key":"10.1016\/j.ijrobp.2014.12.061_bib4","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha emitter radium-223 and survival in metastatic prostate cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2014.12.061_bib5","first-page":"252","article-title":"Targeting of osseous sites with alpha-emitting 223Ra: Comparison with the beta-emitter 89Sr in mice","volume":"44","author":"Henriksen","year":"2003","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ijrobp.2014.12.061_bib6","doi-asserted-by":"crossref","first-page":"4451","DOI":"10.1158\/1078-0432.CCR-04-2244","article-title":"First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases","volume":"11","author":"Nilsson","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2014.12.061_bib7","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s00259-012-2265-y","article-title":"Dosimetry of 223Ra-chloride: Dose to normal organs and tissues","volume":"40","author":"Lassmann","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ijrobp.2014.12.061_bib8","doi-asserted-by":"crossref","first-page":"4077","DOI":"10.1182\/blood-2008-12-192922","article-title":"Spatial gradients of blood vessels and hematopoietic stem and progenitor cells within the marrow cavities of the human skeleton","volume":"114","author":"Bourke","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.ijrobp.2014.12.061_bib9","doi-asserted-by":"crossref","first-page":"645","DOI":"10.2967\/jnumed.106.035337","article-title":"Spatial distribution of blood vessels and CD34+ hematopoietic stem and progenitor cells within the marrow cavities of human cancellous bone","volume":"48","author":"Watchman","year":"2007","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ijrobp.2014.12.061_bib10","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1088\/0031-9155\/57\/10\/3207","article-title":"A bone marrow toxicity model for 223Ra alpha-emitter radiopharmaceutical therapy","volume":"57","author":"Hobbs","year":"2012","journal-title":"Phys Med Biol"},{"key":"10.1016\/j.ijrobp.2014.12.061_bib11","series-title":"Phase I, Open-Label, Dosimetry, Biodistribution and Pharmacokinetic Study of Alpharadin in Patients with Hormone Refractory Prostate Cancer and Skeletal Metastases","author":"Parker","year":"2011"},{"key":"10.1016\/j.ijrobp.2014.12.061_bib12","author":"Morris","year":"2012"},{"key":"10.1016\/j.ijrobp.2014.12.061_bib13","series-title":"Publication 67: Age-Dependent Doses to Members of the Public from Intake of Radionuclides\u2014Part 2: Ingestion Dose Coefficients","author":"International Commission on Radiation Protection","year":"1993"},{"key":"10.1016\/j.ijrobp.2014.12.061_bib14","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1097\/HP.0b013e3182a82b37","article-title":"Radiation safety considerations for the use of 223RaCl2 in men with castration-resistant prostate cancer","volume":"106","author":"Dauer","year":"2014","journal-title":"Health Phys"},{"key":"10.1016\/j.ijrobp.2014.12.061_bib15","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/j.ijrobp.2005.11.036","article-title":"Mitigation of radiation nephropathy after internal alpha-particle irradiation of kidneys","volume":"64","author":"Jaggi","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2014.12.061_bib16","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1088\/0031-9155\/56\/3\/012","article-title":"Renal uptake of bismuth-213 and its contribution to kidney radiation dose following administration of actinium-225-labeled antibody","volume":"56","author":"Schwartz","year":"2011","journal-title":"Phys Med Biol"},{"key":"10.1016\/j.ijrobp.2014.12.061_bib17","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1007\/s00259-013-2427-6","article-title":"Phase I pharmacokinetic and biodistribution study with escalating doses of 223ra-dichloride in men with castration-resistant metastatic prostate cancer","volume":"40","author":"Carrasquillo","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ijrobp.2014.12.061_bib18","series-title":"Gastrointestinal Radiology","author":"Plavsic","year":"1992"},{"key":"10.1016\/j.ijrobp.2014.12.061_bib19","first-page":"3120","article-title":"Significant antitumor effect from bone-seeking, alpha-particle-emitting 223Ra demonstrated in an experimental skeletal metastases model","volume":"62","author":"Henriksen","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.ijrobp.2014.12.061_bib20","first-page":"144","article-title":"Mechanisms of bone metastasis","volume":"4","author":"Roodman","year":"2004","journal-title":"Discov Med"},{"key":"10.1016\/j.ijrobp.2014.12.061_bib21","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1023\/A:1006106209527","article-title":"Mechanisms, hypotheses and questions regarding prostate cancer micrometastases to bone","volume":"17","author":"Lange","year":"1998","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.ijrobp.2014.12.061_bib22","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/SPC.0b013e3283499caa","article-title":"Radiation for bone metastases","volume":"5","author":"Bourgeois","year":"2011","journal-title":"Curr Opin Support Palliat Care"},{"key":"10.1016\/j.ijrobp.2014.12.061_bib23","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/00004032-200401000-00007","article-title":"Biokinetic model of radium in humans and beagles","volume":"86","author":"Polig","year":"2004","journal-title":"Health Phys"},{"key":"10.1016\/j.ijrobp.2014.12.061_bib24","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1093\/jnci\/djt116","article-title":"Survival benefit with radium-223 dichloride in a mouse model of breast cancer bone metastasis","volume":"105","author":"Suominen","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ijrobp.2014.12.061_bib25","first-page":"S290","article-title":"Phase 1 study of alpharadin (223Ra) an alpha-emitting bone-seeking agent in patients with skeletal metastases","volume":"31","author":"Nilsson","year":"2004","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ijrobp.2014.12.061_bib26","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.clgc.2012.07.002","article-title":"Two-year survival follow-up of the randomized, double-blind, placebo-controlled phase II study of radium-223 chloride in patients with castration-resistant prostate cancer and bone metastases","volume":"11","author":"Nilsson","year":"2013","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.ijrobp.2014.12.061_bib27","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.eururo.2012.09.008","article-title":"A randomized, double-blind, dose-finding, multicenter, phase 2 study of radium chloride (Ra 223) in patients with bone metastases and castration-resistant prostate cancer","volume":"63","author":"Parker","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.ijrobp.2014.12.061_bib28","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S1470-2045(14)70183-4","article-title":"Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: Results from a phase 3, double-blind, randomised trial","volume":"15","author":"Sartor","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2014.12.061_bib29","series-title":"Therapeutic Nuclear Medicine","first-page":"447","article-title":"Treatment of osteoblastic skeletal metastases by the alpha-emitting bone-seeker radium-223","author":"Bruland","year":"2014"},{"key":"10.1016\/j.ijrobp.2014.12.061_bib30","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2013.31.6_suppl.19","article-title":"Pain analysis from the phase III randomized ALSYMPCA study with radium-223 dichloride (ra-223) in patients with castration-resistant prostate cancer (CRPC) with bone metastases","volume":"31","author":"Nilsson","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2014.12.061_bib31","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1001\/jama.1990.03450050072031","article-title":"Radithor and the era of mild radium therapy","volume":"264","author":"Macklis","year":"1990","journal-title":"JAMA"},{"key":"10.1016\/j.ijrobp.2014.12.061_bib32","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s00393-005-0009-0","article-title":"Effectiveness and safety of radium chloride in the treatment of ankylosing spondylitis. Results of an observational study","volume":"65","author":"Alberding","year":"2006","journal-title":"Z Rheumatol"},{"key":"10.1016\/j.ijrobp.2014.12.061_bib33","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/HP.0b013e3181cb857f","article-title":"Life-span study on late effects of 224ra in children and adults","volume":"99","author":"Spiess","year":"2010","journal-title":"Health Phys"},{"key":"10.1016\/j.ijrobp.2014.12.061_bib34","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1093\/rheumatology\/ken060","article-title":"Increased risk of myeloid leukaemia in patients with ankylosing spondylitis following treatment with radium-224","volume":"47","author":"Wick","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ijrobp.2014.12.061_bib35","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s10549-014-2939-1","article-title":"A phase IIa, nonrandomized study of radium-223 dichloride in advanced breast cancer patients with bone-dominant disease","volume":"145","author":"Coleman","year":"2014","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ijrobp.2014.12.061_bib36","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1158\/1078-0432.CCR-08-1261","article-title":"A phase I study of samarium lexidronam\/bortezomib combination therapy for the treatment of relapsed or refractory multiple myeloma","volume":"15","author":"Berenson","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2014.12.061_bib37","doi-asserted-by":"crossref","first-page":"381","DOI":"10.3109\/02841869609101655","article-title":"Targeted radiotherapy of osteosarcoma using 153 Sm-EDTMP. A new promising approach","volume":"35","author":"Bruland","year":"1996","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ijrobp.2014.12.061_bib38","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1200\/JCO.20.1.189","article-title":"High-dose samarium-153 ethylene diamine tetramethylene phosphonate: Low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases","volume":"20","author":"Anderson","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2014.12.061_bib39","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1200\/JCO.2002.20.7.1953","article-title":"High-dose samarium-153 ethylene diamine tetramethylene phosphonate: Low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases","volume":"20","author":"Franzius","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2014.12.061_bib40","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/978-3-319-04843-7_16","article-title":"Bone-seeking radiopharmaceuticals as targeted agents of osteosarcoma: Samarium-153-EDTMP and radium-223","volume":"804","author":"Anderson","year":"2014","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.ijrobp.2014.12.061_bib41","doi-asserted-by":"crossref","first-page":"898","DOI":"10.4161\/cbt.6.6.4097","article-title":"Pharmacokinetics and toxicity of 213Bi-labeled PIA2 in preclinical targeted alpha therapy for cancer","volume":"6","author":"Song","year":"2007","journal-title":"Cancer Biol Ther"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301615000061?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301615000061?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,22]],"date-time":"2019-08-22T05:11:45Z","timestamp":1566450705000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301615000061"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["S0360301615000061"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2014.12.061","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2015,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Radium-223 in the Treatment of Osteoblastic Metastases: A Critical Clinical Review","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2014.12.061","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}